Abstracts tagged "Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD)"

Abstract Number: 879 • 2016 ACR/ARHP Annual Meeting
Associated Inflammatory Diseases in Takayasu’s Arteritis: The Many Faces of a Disease
Sinem Nihal Esatoglu¹, Ayse Merve Celik², Didar Ucar³, Aykut Ferhat Celik⁴, Serdal Ugurlu⁵, Gulen Hatemi⁵, Melike Melikoglu⁵, Izzet Fresko⁵, Vedat Hamuryudan⁵, Huri Ozdogan⁶, Sebahattin Yurdakul⁵, Hasan Yazici⁵ and Emire Seyahi⁵, ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: Case reports and series suggest that Takayasu’s arteritis (TA) can co-exist with various inflammatory disorders. Inflammatory bowel disease [(IBD; Crohn's disease (CD) or ulcerative…
Abstract Number: 687 • 2015 ACR/ARHP Annual Meeting
Mucosal Dysregulation in First-Degree Relatives of Ankylosing Spondylitis Patients
Amy Sargious Kehl¹, Carol Landers², Tina Wu², Dermot McGovern³ and Michael H. Weisman¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Department of Inflammatory Bowel & Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: It has been observed that ankylosing spondylitis (AS) patients have a high frequency of asymptomatic chronic gut inflammation, with as many as 60% of…
Abstract Number: 2488 • 2013 ACR/ARHP Annual Meeting
Elevated Serum Anti-Flagellin Antibodies Implicate Subclinical Bowel Inflammation in Ankylosing Spondylitis
Dinny Wallis¹, Arundip Asaduzzaman¹, Michael H. Weisman², Nigil Haroon¹, Ammepa Anton³, Dermot P. B. McGovern⁴, Stephan R. Targan⁵ and Robert D. Inman⁶, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Cedars-Sinai Med Ctr, Los Angeles, CA, ³Rheumatology, University Health Network, Toronto, ON, Canada, ⁴Department of Inflammatory Bowel & Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitisBackground/Purpose: Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) share genetic and clinical features. IBD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].